Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fibrocor Therapeutics LP

https://fibrocortherapeutics.net

Latest From Fibrocor Therapeutics LP

Galapagos Targets Liver Fibrosis With Evotec Deal

Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.

 

Clinical Trials Deals

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.

Business Strategies Commercial

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Fibrocor Therapeutics LP
  • Senior Management
  • Mark Steedman, Pres. & CEO
  • Contact Info
  • Fibrocor Therapeutics LP
    661 University Ave., Ste. 465
    Toronto, M5G 1L6
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register